- Medical School - Washington University School of Medicine in St. Louis (1986-1990)
- Fellowship - Massachusetts General Hospitlal--Postdoctoral Research Fellow, Neuroscience (1990-1992)
- Residency - Columbia University (Department of Neurology) (1993-1996)
- Fellowship - Columbia University, Movement Disorder Fellow (1996-1997)
- Fellowship - Columbia University, Postdoctoral Research Fellow, Neuroscience (1997-2001)
- Internship - Beth Isreal Hospital (1992-1993)
William Dauer, M.D.
Peter O'Donnell Jr. Brain Institute
- Lois C.A. and Darwin E. Smith Distinguished Chair in Neurological Mobility Research
William T. Dauer, M.D., is the inaugural Director of the Peter O’Donnell Jr. Brain Institute and a Professor of Neurology and Neuroscience at UT Southwestern Medical Center. A neurologist acclaimed for his research into dystonia and Parkinson’s disease, he holds the Lois C.A. and Darwin E. Smith Distinguished Chair in Neurological Mobility Research.
Dr. Dauer earned his medical degree at Washington University School of Medicine in St. Louis. After completing an internship at Beth Israel Hospital in Boston, he became a neurology resident and fellow in movement disorders at Columbia University. He pursued postdoctoral work in the Columbia laboratory of René Hen, Ph.D., where he studied the resistance of alpha-synuclein null mice to a toxin that can provoke Parkinson’s in humans.
For nearly two decades, Dr. Dauer’s groundbreaking research has been focused on the molecular basis of dystonia and the mechanisms of neurodegeneration in Parkinson’s disease. His findings have elucidated the critical role of the torsinA protein in the progression of dystonia, which is marked by disabling, involuntary movements. Studies taking place under his direction focused on the neurobiologic basis of falls in Parkinson’s disease are being used to pioneer a novel therapy for this currently untreatable symptom.
Prior to joining the UT Southwestern faculty in 2019, Dr. Dauer served as Director of the Movement Disorders Group and Director of the Morris K. Udall Center of Excellence for Parkinson’s Disease Research at the University of Michigan, where he was also a Professor of Neurology and Cell and Developmental Biology.
He is an elected member of the American Society for Clinical Investigation, and his work has been recognized with the Dystonia Medical Research Foundation’s Fahn Award and the Harold and Golden Lamport Award for excellence in clinical science research from Columbia University.
- American Academy of Neurology (1994)
- Movement Disorders Society (1996)
- Society for Neuroscience (1998)
- American Society for Cell Biology (2004)
- American Neurological Association (2008)
- American Society of Clinical Investigation (2009)
- Board of Scientific Counselors, National Institute of Child Health and Human Development (NICHD) 2018-2023
- Elected to the American Society of Clinical Investigation 2009
- Chair, Chronic Dysfunction and Integrative Neurodegeneration ("CDIN") Study Section 2014-2016
- Elected to American Neurological Association 2008
- Fahn Award 2006, Dystonia Medical Research Foundation, for excellence in dystonia research; first recipient
- Young Investigator Scholarship, Pediatric Neurotransmitter Disease Association 2002
- Danziger Fellow in Movement Disorders, Parkinson's Disease Foundation 1997
Cholinergic system changes of falls and freezing of gait in Parkinson's disease.
Bohnen NI, Kanel P, Zhou Z, Koeppe RA, Frey KA, Dauer WT, Albin RL, Müller MLTM, Annals of neurology 2019 Apr 85 4 538-549
TorsinA dysfunction causes persistent neuronal nuclear pore defects.
Pappas SS, Liang CC, Kim S, Rivera CO, Dauer WT, Human molecular genetics 2018 02 27 3 407-420
Cholinergic interneurons drive maladaptive changes in thalamostriatal circuitry after dopamine depletion.
Li J, Dauer W, Movement disorders : official journal of the Movement Disorder Society 2019 05 34 5 682
A cell autonomous torsinA requirement for cholinergic neuron survival and motor control.
Pappas SS, Li J, LeWitt TM, Kim JK, Monani UR, Dauer WT, eLife 2018 08 7
The DYT6 Dystonia Protein THAP1 Regulates Myelination within the Oligodendrocyte Lineage.
Yellajoshyula D, Liang CC, Pappas SS, Penati S, Yang A, Mecano R, Kumaran R, Jou S, Cookson MR, Dauer WT, Developmental cell 2017 07 42 1 52-67.e4
Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.
Albin RL, Surmeier DJ, Tubert C, Sarter M, Müller MLTM, Bohnen NI, Dauer WT, Movement disorders : official journal of the Movement Disorder Society 2018 12 33 12 1871-1875
TorsinB overexpression prevents abnormal twisting in DYT1 dystonia mouse models.
Li J, Liang CC, Pappas SS, Dauer WT, eLife 2020 03 9
a4ß2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders.
Albin RL, Müller MLTM, Bohnen NI, Spino C, Sarter M, Koeppe RA, Szpara A, Kim K, Lustig C, Dauer WT, Annals of neurology 2021 Jul 90 1 130-142
THAP1 modulates oligodendrocyte maturation by regulating ECM degradation in lysosomes.
Yellajoshyula D, Pappas SS, Rogers AE, Choudhury B, Reed X, Ding J, Cookson MR, Shakkottai VG, Giger RJ, Dauer WT, Proceedings of the National Academy of Sciences of the United States of America 2021 Aug 118 31
CNS critical periods: implications for dystonia and other neurodevelopmental disorders.
Li J, Kim S, Pappas SS, Dauer WT, JCI insight 2021 Feb 6 4
TorsinA restoration in a mouse model identifies a critical therapeutic window for DYT1 dystonia.
Li J, Levin DS, Kim AJ, Pappas SS, Dauer WT, The Journal of clinical investigation 2021 Mar 131 6
- Cholinergic system changes of falls and freezing of gait in Parkinson's disease.
- Pathogenesis of diseases of the motor system
- Parkinson's disease
- Mechanisms underlying selective susceptibility of cells to disease
- Genetics of human disease
- Basal Ganglia